Molecular Docking and ADME Analysis of L-Phe -L-Tyr Dipeptide
-
Published:2022-12-27
Issue:4
Volume:43
Page:739-745
-
ISSN:2587-2680
-
Container-title:Cumhuriyet Science Journal
-
language:en
-
Short-container-title:CSJ
Author:
BIÇAK Bilge1ORCID, GUNDUZ Serda Kecel1
Affiliation:
1. ISTANBUL UNIVERSITY, FACULTY OF SCIENCE
Abstract
Hypertension is a serious risk factor for various diseases. Therefore, lowering and preventing high blood pressure is a significant issue. Blockage of the renin-angiotensin-aldosterone system (RAAS), which controls blood pressure, is important to reduce blood pressure and consequently reduce symptoms of heart failure. This blockage can be carried out by angiotensin-converting enzyme (ACE) and angiotensin II receptor blockers (ARBs). The phenylalanyltyrosine (H-Phe-Tyr-OH, Phe-Tyr, L-Phe-L-Tyr, L-phenylalanyl-L-tyrosine) dipeptide examined in this study is an important structure that shows blood pressure lowering properties. For this reason, the potential of the peptide to be an ACE inhibitor or ARB was investigated. The molecular activity of the Phe-Tyr dipeptide was compared with antihypertensive drugs using theoretical calculations. Molecular docking method, one of these theoretical methods, has a considerable process in illuminating biochemical processes by investigating the interactions of drugs (ligands) with targeted receptors. In this theoretical study, molecular docking analyses of H-Phe-Tyr-OH dipeptide with ACE and Angiotensin II type 1 receptor (AT1R) were implemented. The interaction types and interaction regions of the peptide were also determined in comparison with drug molecules (Captopril, Enalapril, Telmisartan and Eprosartan) that are ACE inhibitors and ARBs. Lastly, ADME (absorption, distribution, metabolism, and excretion) analysis of the H-Phe-Tyr-OH dipeptide was also performed to estimate its drug potential. In this study, the pharmacokinetic properties of Phe-Tyr dipeptide and its mechanism of action with ACE and AT1R were investigated for the first time by molecular docking and ADME calculations.
Publisher
Cumhuriyet University
Reference35 articles.
1. [1] Laurent, S., Antihypertensive drugs, Pharmacol. Res., 124 (2017) 116-125. 2. [2] Hill R.D., Vaidya P.N., Angiotensin II Receptor Blockers (ARB). In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL), (2022). 3. [3] Shahoud, J. S., Terrence S., and Narothama R.A., Physiology, arterial pressure regulation. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL), (2022). 4. [4] Kritsi, E., Matsoukas, M.T., Potamitis, C., Karageorgos, V., Detsi, A., Magafa, V., Liapakis, G., Mavromoustakos, T., Zoumpoulakis, P., Exploring new scaffolds for angiotensin II receptor antagonism, Bioorg. Med. Chem., 24 (18) (2016) 4444-4451. 5. [5] Amaya, J.A.G., Cabrera, D.Z., Matallana, A.M., Arevalo, K.G., Guevara-Pulido, J., In-silico design of new enalapril analogs (ACE inhibitors) using QSAR and molecular docking models, Inform. Med. Unlocked., 19 (2020) 100336.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|